1. Introduction {#s0005}
===============

Ketamine is an uncompetitive *N*-methyl-[d]{.smallcaps}-aspartate (NMDA) receptor antagonist used in healthy volunteers as a safe, transient model of the symptoms of schizophrenia ([@bb0195]; [@bb0200]). Ketamine induces delusion-like ideas, thought disorder, tangential speech, negative symptoms, working memory (WM) deficits, and illusory percepts ([@bb0095]; [@bb0135]; [@bb0010]). Similarities between the neural effects of ketamine and findings in schizophrenia (reviewed in: [@bb0175] & [@bb0160]) have also supported ketamine\'s use in modeling these symptoms ([@bb0200]; [@bb0205]). This work has implicated perturbed NMDA receptor function and glutamate transmission in the pathophysiology of schizophrenia ([@bb0040]). Interestingly, ketamine has also been shown to have affects on mood symptoms and act as a rapid-acting antidepressant, which is not relevant to its use as a model of schizophrenia but could be relevant to some of the changes in brain connectivity previous reported under ketamine.

There is a vastly expanding literature on changes in functional connectivity (fc) observed in patients with schizophrenia, particularly during resting state ([@bb0140]; [@bb0020]; [@bb0025]; [@bb0210]; [@bb0330]). It would be useful to determine which biomarkers associated with schizophrenia are also present following ketamine infusions, and whether these correlate with various psychotic symptoms specifically. This is important for making inferences about the relationships between NMDA dysfunction, fc changes, and symptoms of schizophrenia. We assessed changes in fc in participants given relatively high doses of ketamine compared to saline infusion during rest. We focused on those changes highlighted by meta-analyses of resting fc in schizophrenia ([@bb0285]; [@bb0220]) that have a relationship with psychotic symptoms in patients ([@bb0305]; [@bb0330]; [@bb0155]). Others have recently studied the effects of ketamine on connectivity with some of these regions at sub-anesthetic ([@bb0235]) and various anesthetic ([@bb0055]) doses. However, we were particularly interested in the relationships of these functional connectivity changes with psychotic symptoms, so we used higher sub-anasthetic doses of ketamine and a greater number of participants administered ketamine in order to assess these symptom correlations.

First, we assayed fc of the default-mode network (DMN), particularly with regions within "task-positive networks" including the dorsal attention network (DAN) and fronto-parietal control network (FPN). The default mode network is generally more active during "rest" scans or social cognition tasks, whereas these task positive networks (TPN) are generally more active during tasks such as those involving working memory than rest (reviewed in [@bb0260]). Therefore these networks have an anti-correlated relationship with each other. A decrease in this standard anti-correlation between the DMN and the FPN has been observed in patients with schizophrenia during both rest and a WM task, and this correlated with WM performance and positive symptoms ([@bb0305]). This has also been shown in participants given ketamine during a WM task ([@bb0015]). Similarly, disruptions in fc between the DMN and DAN have been observed in patients with schizophrenia during rest ([@bb0210]) and during a WM task ([@bb0330]), although the directions of change varied across sub-regions of these networks at rest ([@bb0210]). We conducted seed-based analyses using the average time series of all of the combined regions within each of these networks in order to determine whether large-scale network dynamics were altered by ketamine at rest. Unlike previous work using a representative seed within each network ([@bb0235]), we wanted to explore the interactions between these networks as a whole. Our results also led us to follow up with a specific analysis of the differences in connectivity, under ketamine versus saline, between the "salience network" (SAL) and the DAN, FPN and DMN. The salience network has been shown to mediate the anti-correlation between task positive networks and the DMN ([@bb0075]; [@bb0335]).

Next, we assessed the effects of ketamine on connectivity between the right DLPFC and other voxels in the brain compared to saline. The DLPFC is a region within the FPN that has consistently been implicated in working memory deficits in schizophrenia ([@bb0010]; [@bb0140]; [@bb0090]; [@bb0305]), as well as prediction error deficits and delusions in psychosis for the right DLPFC specifically ([@bb0090]; [@bb0100]). Similarly, participants given ketamine show working memory deficits and coinciding alterations in DLPFC connectivity during WM tasks ([@bb0135]). NMDA dysfunction may therefore play a role in the DLPFC dysconnectivity and WM impairment in schizophrenia. Additionally, in patients with schizophrenia, the strongest shift in the anti-correlation of task positive regions with seeds of the DMN has been observed in the right DLPFC during rest ([@bb0305]). This has inspired others to explore alterations in DLPFC fc under ketamine during rest as a representation of task-positive network connectivity changes ([@bb0235]). Our combination of the FPN network and a more targeted right DLPFC-based analysis could identify region-specific trends in addition to the large-scale network dynamics under ketamine during rest in the same group of participants.

We also examined the effect of ketamine versus saline on connectivity between two nuclei within the thalamus and the rest of the brain. In patients with schizophrenia, alterations in the connectivity between the thalamus and sensory-motor cortices, as well as prefrontal, striatal and cerebellar regions have been reported ([@bb0020]; [@bb0220]; [@bb0155]), and shown to correlate with positive symptoms ([@bb0155]). These effects were shown to be localized to two nuclei of the thalamus that are heavily connected with the PFC and primary visual cortex: the medio-dorsal (MD) nucleus and lateral geniculate nucleus (LGN) ([@bb0020]). Using the MD nucleus and the LGN as seeds, [@bb0020] showed that both of these nuclei have uniquely altered connectivity patterns in patients with schizophrenia compared to controls. Additionally, the MD thalamus in particular has well-established structural abnormalities in patients with schizophrenia, which have not been observed in the LGN (reviewed in [@bb5000]). And changes in a BOLD fMRI measure of blood flow in the left medial region of the thalamus under high doses of ketamine correlate positively with perceptual distortion symptoms of psychosis ([@bb0245]). Changes in the LGN *have* been observed in schizoaffective and mood disorder patients, so connectivity with this region of thalamus may play a role in negative mood symptoms not usually observed under ketamine ([@bb0115]; reviewed in [@bb0215]). We sought to assess whether NMDA blockade induces connectivity changes in the LGN and MD thalamus in a way that potentially correlates with psychotic symptoms.

2. Materials and methods {#s0010}
========================

2.1. Subjects {#s0015}
-------------

Fifty-three subjects (previously reported in [@bb0190]), recruited from three academic research institutions, were medically healthy men and women aged 18 to 55 years old (mean(SD) = 31.1(9.6)) without current or past Axis I or II psychiatric or substance history. Exclusion criteria included: a history of recreational use of ketamine, PCP or other NMDAR modulators; adverse reaction to therapeutic ketamine; first-degree relative with schizophrenia; clinically significant history of violence or suicidality; history of significant medical illness, including high blood pressure (\>140/90); significant neurological illness or head injury; pregnancy; current psychotropic medication use; or color blindness.

2.2. Design {#s0020}
-----------

The study was approved by the Local Research Ethics Committees at Yale, Columbia and UC Davis. All subjects gave written informed consent prior to enrollment. Subjects were randomized to ketamine or placebo groups in a 2:1 ratio. More participants were included in the ketamine group in order to increase the range of symptoms for the critical symptom correlation analyses. Subjects participated in two MRI sessions; here we report the results from the resting state fMRI study on infusion day two. Other data for MRS and BOLD task-relevant activation were reported elsewhere ([@bb0190]). The resting scans were acquired 10-min pre and post-ketamine or saline bolus. Clinical assessments were performed following the end of the one-hour infusion. Subjects and clinical researchers were blinded to treatment group. Treatment assignment was randomized and stratified by site so as to minimize site confounds. Demographic information and symptoms induced by ketamine are broken down across site ([Table 1](#t0005){ref-type="table"}).Table 1Demographic data for subjects split into each site where scanning occurred. Symptom Scores and ketamine concentrations also included as mean (standard deviation) values for all subjects receiving ketamine (left) and saline (right) across all three sites. There were significant drug condition by site interaction effects for BPRS-Negative (p = .021), and CADSS-Percept (p = .021) and a main effect of site for CADSS-Percept (0.011). There was also a trending difference across sites for ketamine blood levels (p = .073) but not for nor-ketamine levels (p = .879). Range of possible BPRS scores (20--180), CADSS scores (0--92), POMS (−32−232), BPRS-positive(5--45), BPRS-negative(5--45), and CADSS-perception (0--28).Table 1SiteYaleCUUCSDOverallGender (M/F)5/418/138/531/22Drug condition (K/S)5/420/119/434/19Age, mean (SD), in months331 (57)421 (127)312 (54.8)379 (114)KetamineSalineKetamineSalineKetamineSalineKetamineSalineKetamine levels (ng/mL)139 (63)N/A102 (29)N/A112 (26)N/A111 (31)N/ANor-ketamine levels (ng/mL)63 (29)N/A68 (19)N/A68 (15)N/A67 (19)N/ABPRS24.0 (10.4)20.3 (0.5)23.6 (6.2)21.3 (1.3)22.0 (3.0)20.5 (0.3)23.2 (5.7)20.9 (1.2)CADSS12.4 (12.7)2.0 (3.4)6.2 (7.8)0.8 (1.8)6.4 (6.0)1.5 (1.3)7.2 (8.2)1.2 (2.1)POMS8.6 (23.8)−5.8 (9.6)3.4 (20.6)−6.9 (13.4)3.9 (9.6)3.3 (7.6)4.3 (18.4)−4.5 (11.9)BPRS Negative7.4 (1.7)5.0 (0.0)5.5 (1.2)5.0 (0.0)5.6 (0.7)5.0 (0.0)5.8 (1.3)5.0 (0.0)BPRS Positive9.6 (3.1)5.0 (0.0)6.7 (2.0)5.0 (0.0)7.0 (1.7)5.0 (0.0)7.2 (2.3)5.0 (0.0)CADSS Percept9.2 (8.8)0.0 (0.0)2.8 (3.6)0.4 (0.9)3.3 (3.0)0.0 (0.0)3.9 (4.9)0.2 (0.7)

2.3. Ketamine/placebo infusion {#s0025}
------------------------------

Racemic ketamine hydrochloride (Ketalar; Parke Davis, Morris Plains, NJ) was administered \[0.23 mg/kg bolus over 1 min followed by 0.58 mg/kg/h over 30 min then 0.29 mg/kg/h over 29 min ([@bb0145])\] or placebo (saline). This is the highest dose currently in use in psychiatry research with healthy human subjects ([@bb0145]). Moreover, the paradigm sought to achieve ketamine plasma levels of \~150 ng/mL ([@bb0280]), associated with moderately high psychotomimetic responses ([@bb0145]) in the relative absence of sedation, agitation, or other problematic effects. Ketamine and nor-ketamine levels were measured for all subjects given ketamine, except three from Columbia for technical reasons.

2.4. Clinical and safety measures {#s0030}
---------------------------------

Subjects were rated with the Brief Psychiatric Rating Scale (BPRS), Profile of Mood States (POMS), and Clinician Administered Dissociative Symptom Scale (CADSS) ([@bb0195]). Sub-scores for positive and negative symptoms were extracted from the BPRS, as well as a "Perception" sub-score from the CADSS (which captures aberrant salience experiences). These were used to analyze the relationship between changes in connectivity and symptoms.

2.5. Scanning parameters {#s0035}
------------------------

All fMRI scans were conducted on 3 T scanners at Yale University, Columbia University, or University of California at Davis on the following scanners respectively: 3 T Siemens TIM TRIO, 3 T GE MR750, and 3 T Siemens TIM TRIO. All sites used a 32-channel head coil. The same scanning parameters were used across all sites (detailed scanner specifications can be found in [@bb0190]). Briefly, before initial resting state scans, high-resolution T1\*weighted anatomical images were acquired for image registration (TR = 1900 ms, TE = 2.98 ms, TI = 1100 ms, matrix = 256 × 256, FOV = 256 mm, voxel size = 1.0 × 1.0 × 1.0mm). Then for both pre-drug baseline and post-drug functional imaging, 32 axial-oblique slices were obtained in an interleaved pattern (TR = 200 ms, TE = 30.0ms, FOV = 220 mm, matrix = 64\*64, slice thickness = 4 .0mm, one voxel = 3.4 × 3.4 × 4.0mm).

2.6. Image processing {#s0040}
---------------------

Images were pre-processed in MNI space and functional connectivity was analyzed in CONN functional connectivity toolbox version 17 ([@bb0300]; <https://www.nitrc.org/projects/conn/>), running in Matlab version R2016b (Mathworks, Inc., Natick, MA, USA). The default pre-processing pipeline for volume-based analyses was used with: realignment, slice-timing correction, normalization, ART outlier identification, spatial and temporal filtering, and structural segmentation/normalization to Montreal Neurological Institute (MNI) space. The ART procedure ([@bb0305]) was used for artifact detection. Volumes in which the normalized z-scores from global mean signal intensity exceeded 9 or the framewise composite displacement was over 2 mm in x, y or z translations or 0.9 degrees in the pitch, roll or yaw rotations were identified as outliers. These outlier time points, likely caused by head motion, were then regressed out as nuisance covariates and analyses were conducted to determine whether there were differences in various motion parameters across the drug conditions ([Table 2](#t0010){ref-type="table"}). Cerebrospinal fluid (CSF) and white matter (WM) BOLD signal noise were identified via simultaneous normalization/segmentation procedures using posterior probability maps in this normalized space as Gray/White/CSF masks which were thresholded at 0.5 for WM and CSF. Further one-voxel erosion procedures were used to avoid partial volume effects. These masks were then used by the aCompCorr (analytical component-based noise correction; [@bb0045]) method in this toolbox, to identify and regress out physiological noise in the gray matter regions with the principal component-based noise-correction. This method has been validated as effective in identifying meaningful anti-correlations in resting-state data ([@bb0065]). After white matter, CSF, and realignment/motion outlier confounds were removed, BOLD signal de-spiking was performed using a continuous hyperbolic tangent squashing function in the toolbox to further reduce the influence of outlier scans. Next, images were band-pass filtered using SPM-based Fast Fourier Transformation (FFT) methods (0.0078--0 .1Hz). All EPI-BOLD images were registered to the high-resolution T1\*weighted structural images, and then to MNI space. Finally, a 6 mm full-width half-maximum (FWHM) Gaussian kernel was used for smoothing. All correlation coefficients were converted to normally distributed z-scores for first-level analyses to allow for second-level GLM analyses.Table 2Means (standard deviations) of the maximum and average framewise displacement due to head motion, as determined by ART procedures, displayed across scanning site and in each drug condition.Table 2Average subject motionMaximum subject motionSite Yale0.03312 (0.0509)0.309 (0.2437) Columbia0.00251 (0.0757)0.25 (0.2167) UC-Davis0.03768 (0.0956)0.25 (0.1883)Drug Saline0.0325 (0.0722)0.313 (0.2586) Ketamine0.0187 (0.0884)0.231 (0.1672)

2.7. Large-scale networks {#s0045}
-------------------------

The large-scale network analyses were conducted between DMN, DAN, FPN and the atlas provided in CONN to parcellate the whole brain into functional sub-regions. The CONN atlas comprises 116 subcortical and cortical regions from the Harvard-Oxford Atlas and 16 cerebellar regions from the AAL atlas.

The ROIs for DMN, FPN DAN and SAL were comprised using 10 mm spheres for the sub-regions of each network (coordinates for each sub-region in Supplemental Table 1; taken from [@bb0250], derived from [@bb0120] and [@bb0265]). We combined these sub-regions into a single ROI to establish the respective network masks for DMN, DAN and FPN, with which we explored whole-network dynamics. A false discovery rate (FDR)-correction was applied to all p-values for these four large-scale network analyses separately, and p(FDR) \< 0.05 is reported ([@bb0050]).

Our follow-up analysis with the salience network also used the combined sub-regions of the network as the seed (coordinates in Supplemental Table 1; taken from [@bb0295]) and included only our DMN, FPN, and DAN ROIs as well as sub-regions of these networks from CONN\'s default atlas, which were previously determined from an ICA analysis done in CONN using 498 subjects from the Human Connectome Project (<https://www.nitrc.org/projects/conn/>). The same thresholding procedure was followed.

2.8. DLPFC {#s0050}
----------

The right DLPFC was set as a seed region, and correlations were calculated between this seed and all other voxels in the brain. The coordinates of the 10 mm sphere for this seed are listed in Supplemental Table 1. A voxel-level height threshold of p \< .001 was applied to these analyses, and then the resulting supra-threshold clusters were reported as significant only with cluster-level false discovery rate (FDR)-corrected p-values \<.05 ([@bb0050]).

2.9. Thalamic nuclei {#s0055}
--------------------

For the seed-to-voxel analyses of thalamic nuclei, masks were created in SPM Anatomy Toolbox ([@bb6000]) using the "visual thalamus" and "MD thalamus" seeds based on functional mapping of the thalamus from [@bb7000]. Correlations between these seed regions and all other voxels were calculated. The same thresholding procedure was used for this analysis as the DLPFC.

2.10. Statistical analysis {#s0060}
--------------------------

Two sample *t*-tests were used to assess differences in demographics (sex, race, age) across treatment groups. To ensure our effects were not driven by motion, *t*-test were used to detect differences across drug groups in average and maximum motion realignment parameters ([Table 2](#t0010){ref-type="table"}). Next, one-way ANOVAs were used to assess the difference in clinical measures across site and drug condition (BPRS, CADSS, POMS) using change in score measures (post-infusion minus pre-infusion) with FDR corrections applied.

All connectivity analyses involved *t*-tests on the difference (post-drug minus pre-drug) in z-scored correlations across brain regions between participants given saline versus ketamine. The scanning site was always entered as a covariate in each of these analyses. Effect sizes in the form of standardized beta values are reported, representing the average difference in Fisher-transformed correlation coefficients between drug groups.

2.11. Symptom correlations {#s0065}
--------------------------

All symptom correlations were conducted between symptoms scores of subjects given ketamine and connectivity values across our various regions of interest. Symptom score correlations for the large-scale network analyses were conducted in R Studio (<http://www.rstudio.com/>). We removed outliers 2 standard deviations from the mean and conducted Spearman rank partial correlations controlling for site with nonparametric permutation tests for significance testing using 10,000 permutations (using the RVAideMemoire package in R; [@bb0180]). Because of our particular interest in psychotic symptoms, we limited our large-scale network symptom analyses to connectivity between regions previous literature has suggested might be important in positive symptoms of psychosis ([@bb0225]; [@bb0245]; Raji et al., 2015). This included connectivity of the DMN with DAN and FPN, as well as our large-scale network connectivity with the putamen and thalamus, which also seem to have important functional connections for regulating DMN and task-positive network dynamics ([@bb8000]). Then FDR-correction was applied to p-values, and only p(FDR) \< 0.05 was reported.

For the DLPFC and thalamic-seed symptom correlation analyses, we did partial correlations in subjects given ketamine, controlling for site with nonparametric, permutation tests with 1000 iterations. A voxel-level height threshold of p \< .001 was applied to the whole brain and then results of cluster-level p(FDR) \< 0.05 were reported.

3. Results {#s0070}
==========

3.1. Sample {#s0075}
-----------

Subjects showed no group differences for average age (p(FDR) = 0.70) or gender distribution (p(FDR) = 0.18) based on drug assignment (34 ketamine/19 placebo). No serious or unexpected adverse events were reported in the study. Ketamine levels were on average 110 ng/mL, which was significantly lower than the target 150 ng/mL blood concentration (p(FDR) \< 0.001; blood levels reported across sites in [Table 1](#t0005){ref-type="table"}).

3.2. Clinical ratings {#s0080}
---------------------

CADSS, BPRS and POMS scores were greater under ketamine compared to saline (main effect of drug condition: p(FDR) = 0.006, 0.03 and 0.019). The BPRS positive (p(FDR) = 0.0001), BPRS-negative (p(FDR) = 0.010 and CADSS-perceptual (p(FDR) = 0.0002) subscales also showed significant changes across ketamine and saline participants.

3.3. Covariates {#s0085}
---------------

There were no differences in average (p(FDR) = 0.564) nor maximum (p(FDR) = 0.33) head motion between the drug conditions. There also were no significant gender differences for any connectivity measure of interest in our analyses (p(FDR) \> 0.33). Our analyses for differences in connectivity across the three sites revealed no effect of site for DLPFC, LGN, or any of the large-scale networks. However, the connectivity between MD thalamus and a cluster of voxels in superior temporal cortex did show a significant effect of site (coordinates: 52, −46, 14; 115 voxels; p(FDR) = 0.0281). This region overlapped with a region that showed significant differences across saline and ketamine (see below) however the effect of ketamine survived when controlling for site in these analyses. There were differences in symptoms evinced by the ketamine treatment across sites (see [Table 1](#t0005){ref-type="table"}), which could possibly be related to a trending difference in ketamine concentrations (p = .073) (but not nor-ketamine concentration (p = .88)) across site. This is why site was included as a covariate in our imaging as well as symptom correlation analyses.

3.4. Large-scale network connectivity {#s0090}
-------------------------------------

In our DMN/DAN/FPN large-scale network analyses, we did not find any effect of ketamine compared to saline on DMN-DAN connectivity (p(FDR) = 0.980) or DMN-FPN connectivity (p(FDR) = 0.0742). However, ketamine increased the correlation between the DMN and a range of regions across the cortex and striatum compared to saline ([Table 3](#t0015){ref-type="table"}) including the anterior cingulate cortex (ACC) ([Fig. 1](#f0005){ref-type="fig"}a), posterior cingulate cortex (PCC) ([Fig. 1](#f0005){ref-type="fig"}b), left nucleus accumbens ([Fig. 1](#f0005){ref-type="fig"}c), bilateral insula ([Fig. 1](#f0005){ref-type="fig"}d and e), right paracingulate gyrus ([Fig. 1](#f0005){ref-type="fig"}f) and right frontal pole ([Fig. 1](#f0005){ref-type="fig"}g).Table 3Statistics including Fisher-transformed connectivity mean (standard deviation) values, *t*-value, standardized Beta, and FDR-corrected p-value in each cluster identified by seed-to-voxel and large-scale network analyses comparing saline and ketamine. All *t*-values and p(FDR)-corrected values for symptom correlations not reported in text. Beta values are standardized. Coordinates (MNI) and size of cluster also given for seed-to voxel analyses.Table 3Analysis/RegionSizeXYZMean (SD)Statistics (if not reported in text)Large-scale networks DMN-ACC--------K: 0.168 (0.247)t~(49)~ = 4.97, Beta = 0.580, p(FDR) = 0.0012S: 0.103 (0.167) DMN-PCC--------K: 0.644 (0.260)t~(49)~ = 3.66, Beta = 0.463, p(FDR) = 0.0228S: 0.596 (0.236) DMN-L Nuc Accumbens--------K: −0.146 (0.370)t~(49)~ = 3.20, Beta = 0.416, p(FDR) = 0.0486;S: 0.070 (0.129) DMN-L Insula--------K: −0.043 (0.188)t~(49)~ = 4.34, Beta = 0.527, p(FDR) = 0.0051S: −0.127 (0.185) DMN-R Insula--------K: −0.070 (0.177)t~(49)~ = 3.65, Beta = 0.462, p(FDR) = 0.0228S: −0.125 (0.176) DMN-R Paracing Gyrus--------K: 0.498 (0.252)t~(49)~ = 3.21, Beta = 0.417, p(FDR) = 0.0486S: 0.427 (0.211) DMN-R Frontal Pole--------K: 0.489 (0.225)t~(49)~ = 3.29, Beta = 0.425, p(FDR) = 0.0486S: 0.496 (0.206) SAL-DMN--------K: 0.260 (0.195)T~(49)~ = 5.59, Beta = 0.624, p(FDR) = 0.000045S: −0.074 (0.236) SAL-L PFC (FPN)--------K: 0.133 (0.212)T~(49)~ = 3.73, Beta = 0.470, p(FDR) = 0.0038S: −0.110 (0.223) SAL-R Lateral Parietal (DMN)--------K: 0.154 (0.185)T~(49)~ = 3.51, Beta = 0.448, p(FDR) = 0.0049S: −0.065 (0.238) SAL-R Posterior Parietal Cortex (FPN)--------K: 0.142 (0.207)T~(49)~ = 2.80, Beta = 0.371, p(FDR) = 0.0274S: −0.025 (0.222)DLPFC R Post-central gyrus12732−4264K: 0.115 (0.166)t~(51)~ = 4.44, Beta = 0.528, p(FDR) = 0.043S: −0.083 (0.162) Pons1274−18−46K: −0.064 (0.097)t~(51)~ = −5.96, Beta = −0.641, p(FDR) = 0.043S: 0.128 (0.127)MD Thalamus R Superior temporal gyrus25142−4010K: 0.197 (0.124)t~(51)~ = 5.69, Beta = 0.623, p(FDR) \< 0.001S: 0.004 (0.147) R Parahippocampal gyrus12418−10−28K: 0.157 (0.105)t~(51)~ = 5.82, Beta = 0.632, p(FDR) = 0.025S: −0.052 (0.158) Symptom correlationsDLPFC-POMS L Frontal Orbital Cortex217−2624−8t~(51)~ = 5.77, Beta = 0.640, p(FDR) = 0.038 ACC19743820t~(51)~ = 5.27, Beta = 0.605, p(FDR) = 0.038Fig. 1Altered connectivity between DMN and various regions of interest in participants given ketamine versus saline. Bars represent average *Z*-score of correlation, error bars are standard error. All post-pre difference scores are significantly different across drug condition, p(FDR) \< 0.05.Fig. 1

Our results showed changes between the large-scale networks and regions of the salience network, which has previously been implicated as important for modulating the relationship between task positive and default mode networks ([@bb0075]; [@bb0335]) and dysfunction in this relationship has been implicated in schizophrenia ([@bb0225]; [@bb0310]). Therefore, we followed up with a direct analysis of the differences in connectivity between the salience network and our default mode and task positive networks. Our findings showed that connectivity between the salience network and whole DMN seed was increased under ketamine, at least in part driven by significant differences in the right lateral parietal seed in the DMN ([Table 3](#t0015){ref-type="table"}; [Fig. 2](#f0010){ref-type="fig"}). There were also increases in salience network connectivity with regions of the FPN, including right posterior parietal cortex and left prefrontal cortex under ketamine ([Table 3](#t0015){ref-type="table"}; [Fig. 2](#f0010){ref-type="fig"}).Fig. 2Altered connectivity between SAL and subregions of the FPN and DMN in participants given ketamine versus saline. Bars represent average Z-score of correlation, error bars are standard error. All difference scores are significantly different across drug condition, p(FDR) \< 0.05.Fig. 2

3.5. DLPFC connectivity {#s0095}
-----------------------

When looking more closely at the dorsolateral PFC within the FPN, we found that connectivity with the DLPFC was disrupted by ketamine in a cluster of voxels in the right post-central gyrus and in the pons ([Fig. 3](#f0015){ref-type="fig"}; [Table 3](#t0015){ref-type="table"}). None of the regions differentially connected with DLPFC under ketamine were part of the DMN or DAN.Fig. 3Clusters with significantly different connectivity with the DLPFC in participants given ketamine versus saline. Color bar indicates *t*-value; p(FDR) \< 0.05.Fig. 3

3.6. Thalamic nuclei connectivity {#s0100}
---------------------------------

Our analyses with the two sub-nuclei of the thalamus (LGN and MD, which exhibit aberrant connectivity in schizophrenia ([@bb0020])), revealed that the MD thalamus evinced increased connectivity with the right superior temporal gyrus in participants given ketamine versus saline ([Table 3](#t0015){ref-type="table"}; [Fig. 4](#f0020){ref-type="fig"}). Part of the right parahippocampal gyrus also showed increased connectivity with the MD nucleus under ketamine. But no differences were found between the saline and ketamine groups for the connectivity between the LGN seed and any other voxels in the brain.Fig. 4Changes in connectivity with the MD thalamus. Representation of areas where connectivity with MD thalamus was altered in participants given ketamine compared to control. Color bar represents *t*-value; p(FDR) \< 0.05.Fig. 4

3.7. Symptom correlations {#s0105}
-------------------------

### 3.7.1. Large-scale networks {#s0110}

Given our interest in ketamine\'s use as a tool to elicit symptoms of psychosis, we investigated how functional connectivity between our network ROIs and regions of thalamus and striatum under ketamine correlated with positive symptom ratings. None of the regions of interest we selected showed a significant relationship with positive symptoms induced under ketamine (p(FDR) \> 0.35).

### 3.7.2. DLPFC-seed {#s0115}

POMS mood scores correlated with DLPFC connectivity with ACC as well as a region of left frontal orbital cortex connectivity ([Table 3](#t0015){ref-type="table"}).

### 3.7.3. Thalamic seeds {#s0120}

Functional connectivity with the MD nucleus of the thalamus did not correlate with any symptom scores in participants given ketamine.

4. Discussion {#s0125}
=============

Our results did not reveal an effect of ketamine compared to saline on DMN-FPN or DMN-DAN connectivity during rest, an effect previously shown in patients with schizophrenia ([@bb0305]; [@bb0165]) and in participants given ketamine during a WM task ([@bb0015]). [@bb0235] similarly found no change in DLPFC connectivity with regions of DMN with a lower dose of ketamine at rest. Although, a dose of ketamine that achieved blood levels over six times those observed in this study did find altered DMN-TPN connectivity ([@bb0055]), so it is possible these large-scale network effects are dose-dependent.

In our study, connectivity between the DMN and ACC, insula, PCC, nucleus accumbens, paracingulate cortex and frontal pole all increased under ketamine compared to saline. The insula is well-placed to influence the balance between bottom-up and top-down processing in predictive coding schemes ([@bb0070]), which has been linked to perceptual distortions in schizophrenia ([@bb0255]).

Notably, the insula and ACC make up the salience network (SAL), a cluster of regions whose connectivity has been shown through effective connectivity analyses to dampen DMN activity and modulate the connectivity between DMN and DAN/FPN in healthy participants ([@bb0075]; [@bb0335]), which have both been shown previously to be disrupted under ketamine during similar WM tasks ([@bb0015]). This motivated us to follow-up with explicit tests of the relationship between the salience network and DMN, DAN and FPN, which revealed an effect of ketamine on connectivity between salience network and regions of both the DMN and FPN. Interestingly, hypo-connectivity between the DMN and SAL has been consistently shown in patients with schizophrenia compared to controls ([@bb0225]; reviewed in [@bb0240]), while our analyses revealed hyper-connectivity amongst these regions. This difference from the effects we found under ketamine could be related to illness course. Previous research has shown ketamine models functional connectivity in first-episode participants better than in chronic patients, and these two patient groups can show opposite patterns of connectivity within the same region ([@bb0030]). Youth at risk of psychosis do show decreased anti-correlation between DMN and SAL, which is consistent with our current results under ketamine ([@bb0310]; see [Table 4](#t0020){ref-type="table"} for a summary of these results across disease progression in relation to our results).Table 4Findings from previous studies of participants with schizophrenia in at-risk, first episode or chronic phases in relation to our results with participants given ketamine.Table 4StudyPatient group (Chronic, first-episode or at-risk schizophrenia)Schizophrenia findingsOur findings with ketamineThalamus[@bb0020]ChronicIncreased connectivity with sensory cortices; decreased connectivity with PFC, striatum and cerebellum- Increased connectivity with primary sensory cortex (auditory);\
- Increased connectivity with parahippocampal gyrus;\
- No regions of decreased connectivity found[@bb0025]ChronicOver-connectivity with sensory-motor regions; decreased connectivity with striatum, prefrontal and cerebellar regions[@bb0155]ChronicDecreased connectivity with cerebellum and ACC; Increased connectivity with regions of visual and auditory cortex, precentral gyrus and lingual gyrus[@bb0035]At-riskIncreased connectivity with sensory cortices; decreased connectivity with PFC, striatum, and cerebellum (especially in future converters)PFC[@bb0030]First-episodeIncreased medial PFC global connectivity- Increased dorsolateral connectivity with post-central gyrus;\
- Decreased DLPFC connectivity with pons.[@bb0030]ChronicReduced lateral PFC global connectivityLarge-scale networks[@bb0305]ChronicIncreased within-DMN connectivity; Decreased anticorrelation between DMN and right DLPFC- Increased connectivity between DMN and Salience network, as well as regions of FPN and Salience network;\
- Increased within-DMN connectivity;\
- DMN connectivity also increase with other regions of striatum, and paracingulate gyrus;\
- No specific changes in right DLPFC or DAN/FPN connectivity with DMN[@bb0225]ChronicDecreased SAL-DMN/CEN connectivity (esp dorsal CEN and superior-posterior DMN)[@bb0310]At-riskIncreased connectivity (decreased anticorrelation) between regions of DMN and task positive network; Increased connectivity (decreased anticorrelation) between DMN and SAL regions[@bb0150]At-risk and first-episodeRegionally specific hypo- and hyper-connectivity in large-scale networks were similar but fewer/smaller regions in at-risk compared to chronic patients.Whole brain[@bb0220]ChronicAlterations in frontal cortex connectivity (mostly increased); changes in thalamic connectivity and other subcortical and limbic patterns of connectivity- No explicit whole brain analyses for frontal cortex analyses.\
- Some thalamic changes replicated with sensory cortices;\
- Frontal lobe connectivity increased with DMN[@bb0220]First-episodeAlterations in frontal cortex connectivity (mostly increased)

Additionally, the PCC and frontal pole are both regions within the DMN, so their altered correlation with our whole DMN seed represents disruptions in intrinsic connectivity within this network at rest under ketamine versus saline. This coincides with previous research demonstrating that patients with schizophrenia have internal hyper-connectivity within DMN nodes, which correlated with positive symptoms ([@bb0305]).

Although our dose of ketamine during rest did not induce significant changes in the DMN-DAN/FPN connectivity, we do see changes in connectivity between these large-scale networks and many regions believed to control the anti-correlation between them (insula, ACC) (Di and Biswal, 2014; [@bb0075]; [@bb0335]); a task condition ([@bb0015]) or higher dose of ketamine ([@bb0055]) may be necessary to elicit disrupted anti-correlations between these networks.

[@bb0235] previously found altered connectivity within-subjects under ketamine versus saline between the DLPFC and ACC, superior frontal gyrus and calcarine fissure, which we did not observe with our higher ketamine dose. We did find a relationship between DLPFC-ACC connectivity and mood symptoms so this may be relevant to this change observed by Mueller and colleagues under ketamine versus saline. Additionally, in line with our large-scale network results and Mueller and colleagues\' findings (2018), the right DLPFC within the FPN did not show altered connectivity with any regions within the DMN under ketamine versus saline. This specific region within the FPN usually evinces the greatest alterations in connectivity with DMN seeds in patients ([@bb0305]); these results together support our conclusion that unlike in schizophrenia, during resting state conditions the alterations in DMN-FPN connectivity are not present or are too weak to reach statistical significance under various sub-anesthetic doses of ketamine. The DLPFC time series showed altered coupled with the ACC in a way that positively correlated with changes in subjects\' mood reports as measured by POMS. While the POMS is a crude measure of mood, these relationships could be relevant to the psychotomimetic and potential antidepressant effects of ketamine. This fits well with previous ideas about the role of the prefrontal cortex connectivity in mood disorders and in ketamine\'s ability to alleviate these symptoms ([@bb0005]). The ACC has also been strongly implicated in mood disorders previously (reviewed in [@bb0130]) and in ketamine\'s (and other NMDA antagonists that do not induce psychotic symptoms) early sites of action for its antidepressant effects ([@bb0125]). Further work is needed to explicitly explore these diverging pathways that may be involved in ketamine\'s effect on mood versus psychosis.

Ketamine has been shown to alter blood flow to the thalamus in a way that correlates with perceptual alterations induced by this drug ([@bb0245]), but to our knowledge nobody has ever looked at specific patterns of thalamic nuclei connectivity in relation to these symptoms. Our results showed various changes in connectivity with MD thalamus. Changes in several structural and synaptic measures have been discovered specifically in the MD nucleus of the thalamus in schizophrenia (reviewed in Pergola et al, 2015), while the LGN may be more involved in negative mood symptoms ([@bb0115]; reviewed in [@bb0215]), so it is not surprising that ketamine elicited altered functional dynamics in the MD thalamus as opposed to LGN. And this demonstrates that the functional effects of ketamine are specific to certain sub-regions of the thalamus as opposed to the entire structure. Prior studies demonstrate that patients with schizophrenia have deficits in thalamic connectivity with association cortices, and hyper-connectivity with sensorimotor and sensory cortices ([@bb0020]; [@bb0025]; [@bb0035]). Our data indicates somewhat different but overlapping patterns of altered thalamic connectivity with ketamine. We found increased mediodorsal thalamic functional connectivity with areas involved in auditory processing in the superior temporal gyrus (in line with previous work), and with parahippocampal gyrus, but no altered connectivity between the LGN and sensorimotor cortices. We also did not find MD thalamus to PFC changes as seen in patients with schizophrenia ([@bb0020]; [@bb0025]; [@bb0035]; see [Table 4](#t0020){ref-type="table"} see [Table 4](#t0020){ref-type="table"} for a summary of these results across disease progression in relation to our results).

Finally, we tested for symptom correlations with positive symptom and mood scales, and did not find any significant relationships between our measures of connectivity in the a priori ROIs and positive symptoms of schizophrenia. This is in line with previous research ([@bb0235]) showing ketamine changes relevant to large-scale task positive and default mode network dynamics do not correlate with positive symptoms. It is possible the changes across drug conditions we observed are more relevant to cognitive and working memory deficits, which were not tested in the present study.

4.1. Limitations {#s0130}
----------------

There are a few limitations that should be noted when interpreting the results of this study. First, the design was a between-subjects design with a baseline scan, which may be less powerful than a within-subjects design with a placebo and ketamine scan. This could have driven some of the differences between the present results and previous studies ([@bb0235]). Second, although the multi-site nature of the study is useful for showing effects of ketamine that are reliable across scanning location, we did see some differences across sites especially related to symptom scores and ketamine blood levels. We controlled for site in all of our analyses to try to account for these differences.

Next, there has been little evidence for the stability of reported CADSS, POMS and BPRS scores following ketamine administration. One study does suggest the CADSS scale has high sensitivity for ketamine\'s effects but low Interclass Correlations across infusions within-subject ([@bb0105]). CADSS scores may not be stable with ketamine infusion, however most of our symptom correlations occur with both BPRS and CADSS subscales with overlapping symptoms measured, suggesting the scales are producing a consistent measure of the participant\'s experience in our study.

4.2. Conclusions {#s0135}
----------------

We sought to investigate the effects of ketamine on functional connectivity using seeds of interest previously identified in patients with schizophrenia. We did find alterations consistent with those observed in patients with schizophrenia, including hyper-connectivity between MD thalamus and sensory cortical regions, as well as increased intra-network connectivity within the DMN. We also provide further support that ketamine may model some fc patterns of early or at-risk patients with psychotic illnesses better than chronic schizophrenia patients ([@bb0030]). We provide a table comparing the results we saw under ketamine with previous results reported in patients with schizophrenia across different stages of illness progression ([Table 4](#t0020){ref-type="table"}). Unsurprisingly, ketamine does not replicate all of the findings from patients with schizophrenia, including altered large-scale network dynamics at rest and thalamic-PFC connectivity. Importantly our results identify possible causal relationships between NMDA signaling disruptions and various alterations in patterns of DMN, thalamic, superior temporal cortical and insular connectivity, which have also been observed in patients with schizophrenia. These signatures may serve as important biomarkers for future work with the use of ketamine as a model of these symptoms, and in understanding ketamine-induced psychosis and psychotic illnesses more generally.
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